Antibody Discovery Market - A Global and Regional Analysis: Focus on Offering, Technology, Antibody Type, Therapeutics, Nature, End User, and Country - Analysis and Forecast, 2025-2035
Description
Global Antibody Discovery Market: Industry Overview
The global antibody discovery market was valued at approximately $11.15 billion in 2025 and is projected to grow $35.35 billion by 2035, at a CAGR of around 12.23%. The global antibody discovery market is rapidly evolving, driven by advancements in engineering technologies, automation, and artificial intelligence. A major trend shaping this growth is the shift toward fully human and humanized antibodies, which improve therapeutic safety, specificity, and efficacy while reducing immunogenicity. Supported by technologies such as phage display, transgenic animal models, and glycoengineering, these formats are transforming treatments for cancer, autoimmune, and infectious diseases. Additionally, the integration of high-throughput screening, next-generation sequencing, and automation has streamlined antibody identification and optimization, significantly shortening development timelines and improving cost efficiency. The increasing reliance on contract research organizations further enhances scalability and accelerates innovation by providing specialized infrastructure and expertise in antibody screening and engineering.
Additionally, artificial intelligence and machine learning are reshaping the discovery process by enabling predictive modeling, affinity optimization, and rapid sequence design. These tools enhance precision and reduce development costs, supporting the growing demand for precision therapies. Innovations such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies are broadening therapeutic potential across oncology, immunology, and rare diseases. Despite challenges such as high production costs and competition from alternative modalities such as gene and cell therapies, continued progress in automation, bioinformatics, and process scalability positions the global antibody discovery market for sustained growth and technological maturity in the coming decade.
Global Antibody Discovery Market Lifecycle Stage
The global antibody discovery market is positioned in the growth stage of its lifecycle, characterized by accelerating innovation, expanding adoption across therapeutic areas, and intensifying competition among established companies and emerging players. The market has evolved beyond early-stage scientific exploration into a mature, technology-driven ecosystem where efficiency, automation, and precision increasingly define competitive advantage. This phase is marked by the rapid integration of artificial intelligence and machine learning-enabled discovery platforms, high-throughput screening, and multi-omics integration, which are significantly reducing development timelines and enhancing candidate success rates.
As the market continues to mature, focus is shifting from innovation-driven discovery toward process optimization, clinical validation, and cost efficiency. Competitive dynamics are expected to intensify as new entrants leverage computational biology and synthetic biology approaches to challenge traditional discovery models. Over the next decade, the global antibody discovery market is anticipated to progress toward the early maturity phase, characterized by broader clinical adoption, standardized workflows, and increasing regulatory clarity.
Market Segmentation:
Segmentation 1: By Offering
Product
Antibody Discovery Platforms & Systems
Kits & Reagents
Antibody Libraries
Others
Services
Antigen Designing & Preparation
Hit Generation & Screening
Lead Selection & Optimization
Antibody Engineering & Characterization
Other Services
Products account for the larger share of the antibody discovery market as they include antibody discovery platforms and systems, kits, reagents, and antibody libraries, among others that are essential, high-value, and recurrently consumed across discovery workflows. While services generate significant revenue, product sales are often bundled into multiple projects, creating a broader revenue base.
Segmentation 2: By Technology
Phage Display Technology
Hybridoma Technology
Single B-Cell Technologies
Transgenic Animal-based Methods
Other Technologies
Phage display technology accounts for the largest share in the antibody discovery market as it allows the screening of very large antibody libraries in vitro, making it highly efficient for isolating binders against diverse and difficult targets. Its ability to generate fully human antibodies without the need for immunization has made it the most widely used technology by pharmaceutical and biotechnology companies and other end users.
Segmentation 3: By Antibody Type
Monoclonal Antibodies
Polyclonal Antibodies
Next-Generation Antibodies
Bispecific Antibodies
Antibody-Drug Conjugates
Nanobodies
Other Engineered Antibodies
Monoclonal antibodies account for the largest share of the global antibody discovery market as they are well-established, widely approved, and form the backbone of therapeutic pipelines across multiple disease areas. However, next-generation antibodies are expected to be the fastest growing segment, driven by the rapid development and clinical success of bispecifics, ADCs, and other engineered formats that offer improved efficacy and novel mechanisms of action.
Segmentation 4: By Nature
Human Antibodies
Humanized Antibodies
Chimeric Antibodies
Murine Antibodies
Human antibodies hold the largest share in the antibody discovery market as they offer the highest compatibility and lowest risk of immunogenicity in patients. Advances in transgenic animal models, phage display, and single B-cell technologies have enabled efficient generation of fully human antibodies, making them the preferred choice as a safe and long-lasting therapeutics.
Segmentation 5: By Therapeutic Area
Oncological Disorders
Immunological Disorders
Infectious Diseases
Cardiovascular Disorders
Neurological Disorders
Other Therapeutic Areas
Oncology disorders account for the largest share of the antibody discovery market because antibodies have become a cornerstone of cancer therapy, with numerous monoclonal antibodies, bispecifics, and ADCs approved and in late-stage pipelines. The high unmet need, significant R&D investment, and rapid adoption of next-generation antibody formats in immuno-oncology drive sustained dominance of this therapeutic area.
Segmentation 6: By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
Others
Based on end-user segmentation, pharmaceutical and biotechnology companies are expected to account for the largest share of the global antibody discovery market in 2024 as they conduct extensive in-house R&D and maintain proprietary discovery platforms to build differentiated pipelines. These companies also actively collaborate with others to accelerate antibody discovery, while leveraging licensing agreements and acquisitions to expand their therapeutic portfolios. Their strong financial capacity and emphasis on advancing next-generation antibody modalities further reinforce their leading role in this market.
Segmentation 7: By Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America is expected to hold the largest share of the global antibody discovery market, driven by the strong presence of major biopharmaceutical companies, advanced research infrastructure, and high R&D investments. The region benefits from early adoption of AI-driven discovery platforms, extensive clinical trial activity, and supportive regulatory frameworks that accelerate biologics development and commercialization.
Demand – Drivers and Limitations
Demand Drivers for the Global Antibody Discovery Market:
Advancements in Antibody Engineering for Therapeutic Applications
Increasing Prevalence of Chronic Diseases
Limitations for the Global Antibody Discovery Market:
Rising Shift toward Alternative Antibody-Based Treatment Modalities
High Costs Restrict Widespread Adoption of Antibody Therapies
How can this report add value to an organization?
Product/Innovation: This report enables organizations to identify high-value opportunities in the global antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.
Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.
Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.
Key Market Players and Competitive Landscape
The global antibody discovery market is characterized by a rapidly evolving and competitive landscape, driven by technological innovation, strategic partnerships, and the growing demand for next-generation therapeutics. The market comprises a mix of well-established biopharmaceutical companies and emerging biotechnology firms specializing in advanced discovery platforms, contract research services, and integrated biologics development as well as contract research organizations. Key players include:
OmniAb Inc.
Twist Bioscience Corporation
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
WuXi Biologics Inc.
Charles River Laboratories International, Inc.
Regeneron Pharmaceuticals, Inc.
FairJourney Biologics S.A.
Samsung Biologics
Genmab A/S
Alloy Therapeutics, Inc.
Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global antibody discovery market.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 1-5 business days to complete the report upon order confirmation.
The global antibody discovery market was valued at approximately $11.15 billion in 2025 and is projected to grow $35.35 billion by 2035, at a CAGR of around 12.23%. The global antibody discovery market is rapidly evolving, driven by advancements in engineering technologies, automation, and artificial intelligence. A major trend shaping this growth is the shift toward fully human and humanized antibodies, which improve therapeutic safety, specificity, and efficacy while reducing immunogenicity. Supported by technologies such as phage display, transgenic animal models, and glycoengineering, these formats are transforming treatments for cancer, autoimmune, and infectious diseases. Additionally, the integration of high-throughput screening, next-generation sequencing, and automation has streamlined antibody identification and optimization, significantly shortening development timelines and improving cost efficiency. The increasing reliance on contract research organizations further enhances scalability and accelerates innovation by providing specialized infrastructure and expertise in antibody screening and engineering.
Additionally, artificial intelligence and machine learning are reshaping the discovery process by enabling predictive modeling, affinity optimization, and rapid sequence design. These tools enhance precision and reduce development costs, supporting the growing demand for precision therapies. Innovations such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies are broadening therapeutic potential across oncology, immunology, and rare diseases. Despite challenges such as high production costs and competition from alternative modalities such as gene and cell therapies, continued progress in automation, bioinformatics, and process scalability positions the global antibody discovery market for sustained growth and technological maturity in the coming decade.
Global Antibody Discovery Market Lifecycle Stage
The global antibody discovery market is positioned in the growth stage of its lifecycle, characterized by accelerating innovation, expanding adoption across therapeutic areas, and intensifying competition among established companies and emerging players. The market has evolved beyond early-stage scientific exploration into a mature, technology-driven ecosystem where efficiency, automation, and precision increasingly define competitive advantage. This phase is marked by the rapid integration of artificial intelligence and machine learning-enabled discovery platforms, high-throughput screening, and multi-omics integration, which are significantly reducing development timelines and enhancing candidate success rates.
As the market continues to mature, focus is shifting from innovation-driven discovery toward process optimization, clinical validation, and cost efficiency. Competitive dynamics are expected to intensify as new entrants leverage computational biology and synthetic biology approaches to challenge traditional discovery models. Over the next decade, the global antibody discovery market is anticipated to progress toward the early maturity phase, characterized by broader clinical adoption, standardized workflows, and increasing regulatory clarity.
Market Segmentation:
Segmentation 1: By Offering
Product
Antibody Discovery Platforms & Systems
Kits & Reagents
Antibody Libraries
Others
Services
Antigen Designing & Preparation
Hit Generation & Screening
Lead Selection & Optimization
Antibody Engineering & Characterization
Other Services
Products account for the larger share of the antibody discovery market as they include antibody discovery platforms and systems, kits, reagents, and antibody libraries, among others that are essential, high-value, and recurrently consumed across discovery workflows. While services generate significant revenue, product sales are often bundled into multiple projects, creating a broader revenue base.
Segmentation 2: By Technology
Phage Display Technology
Hybridoma Technology
Single B-Cell Technologies
Transgenic Animal-based Methods
Other Technologies
Phage display technology accounts for the largest share in the antibody discovery market as it allows the screening of very large antibody libraries in vitro, making it highly efficient for isolating binders against diverse and difficult targets. Its ability to generate fully human antibodies without the need for immunization has made it the most widely used technology by pharmaceutical and biotechnology companies and other end users.
Segmentation 3: By Antibody Type
Monoclonal Antibodies
Polyclonal Antibodies
Next-Generation Antibodies
Bispecific Antibodies
Antibody-Drug Conjugates
Nanobodies
Other Engineered Antibodies
Monoclonal antibodies account for the largest share of the global antibody discovery market as they are well-established, widely approved, and form the backbone of therapeutic pipelines across multiple disease areas. However, next-generation antibodies are expected to be the fastest growing segment, driven by the rapid development and clinical success of bispecifics, ADCs, and other engineered formats that offer improved efficacy and novel mechanisms of action.
Segmentation 4: By Nature
Human Antibodies
Humanized Antibodies
Chimeric Antibodies
Murine Antibodies
Human antibodies hold the largest share in the antibody discovery market as they offer the highest compatibility and lowest risk of immunogenicity in patients. Advances in transgenic animal models, phage display, and single B-cell technologies have enabled efficient generation of fully human antibodies, making them the preferred choice as a safe and long-lasting therapeutics.
Segmentation 5: By Therapeutic Area
Oncological Disorders
Immunological Disorders
Infectious Diseases
Cardiovascular Disorders
Neurological Disorders
Other Therapeutic Areas
Oncology disorders account for the largest share of the antibody discovery market because antibodies have become a cornerstone of cancer therapy, with numerous monoclonal antibodies, bispecifics, and ADCs approved and in late-stage pipelines. The high unmet need, significant R&D investment, and rapid adoption of next-generation antibody formats in immuno-oncology drive sustained dominance of this therapeutic area.
Segmentation 6: By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
Others
Based on end-user segmentation, pharmaceutical and biotechnology companies are expected to account for the largest share of the global antibody discovery market in 2024 as they conduct extensive in-house R&D and maintain proprietary discovery platforms to build differentiated pipelines. These companies also actively collaborate with others to accelerate antibody discovery, while leveraging licensing agreements and acquisitions to expand their therapeutic portfolios. Their strong financial capacity and emphasis on advancing next-generation antibody modalities further reinforce their leading role in this market.
Segmentation 7: By Region
North America
Europe
Asia-Pacific
Rest-of-the-World
North America is expected to hold the largest share of the global antibody discovery market, driven by the strong presence of major biopharmaceutical companies, advanced research infrastructure, and high R&D investments. The region benefits from early adoption of AI-driven discovery platforms, extensive clinical trial activity, and supportive regulatory frameworks that accelerate biologics development and commercialization.
Demand – Drivers and Limitations
Demand Drivers for the Global Antibody Discovery Market:
Advancements in Antibody Engineering for Therapeutic Applications
Increasing Prevalence of Chronic Diseases
Limitations for the Global Antibody Discovery Market:
Rising Shift toward Alternative Antibody-Based Treatment Modalities
High Costs Restrict Widespread Adoption of Antibody Therapies
How can this report add value to an organization?
Product/Innovation: This report enables organizations to identify high-value opportunities in the global antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.
Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.
Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.
Key Market Players and Competitive Landscape
The global antibody discovery market is characterized by a rapidly evolving and competitive landscape, driven by technological innovation, strategic partnerships, and the growing demand for next-generation therapeutics. The market comprises a mix of well-established biopharmaceutical companies and emerging biotechnology firms specializing in advanced discovery platforms, contract research services, and integrated biologics development as well as contract research organizations. Key players include:
OmniAb Inc.
Twist Bioscience Corporation
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
WuXi Biologics Inc.
Charles River Laboratories International, Inc.
Regeneron Pharmaceuticals, Inc.
FairJourney Biologics S.A.
Samsung Biologics
Genmab A/S
Alloy Therapeutics, Inc.
Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global antibody discovery market.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 1-5 business days to complete the report upon order confirmation.
Table of Contents
- Executive Summary
- Scope and Definition
- 1 Market: Industry Outlook
- 1.1 Regulatory Landscape / Compliance
- 1.1.1 U.S.
- 1.1.2 E.U.
- 1.1.2.1 Germany
- 1.1.2.2 France
- 1.1.2.3 Italy
- 1.1.3 Asia-Pacific
- 1.1.3.1 China
- 1.1.3.2 Japan
- 1.1.4 Rest-of-the-World
- 1.1.4.1 Brazil
- 1.1.4.2 U.A.E.
- 1.2 Pricing Analysis
- 1.2.1 By Product
- 1.2.2 By Region
- 1.3 Supply Chain Analysis
- 1.4 Value Chain Analysis
- 1.5 Patent Analysis
- 1.5.1 By Country
- 1.5.2 By Company
- 1.5.3 By Technology
- 1.6 Market Dynamics
- 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
- 1.6.2 Market Trends
- 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
- 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
- 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
- 1.6.3 Market Drivers
- 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
- 1.6.3.2 Increasing Prevalence of Chronic Diseases
- 1.6.4 Market Challenges
- 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
- 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
- 1.6.5 Market Opportunities
- 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery
- 2 Offering
- 2.1 Offering Summary
- 2.2 Antibody Discovery Market (by Products)
- 2.2.1 Antibody Discovery Platforms and Systems
- 2.2.2 Kits and Reagents
- 2.2.3 Antibody Libraries
- 2.2.4 Other Products
- 2.3 Antibody Discovery Market (by Services)
- 2.3.1 Antigen Designing and Preparation
- 2.3.2 Hit Generation and Screening
- 2.3.3 Lead Selection and Optimization
- 2.3.4 Antibody Engineering and Characterization
- 2.3.5 Other Services
- 3 Technology
- 3.1 Technology Summary
- 3.2 Phage Display Technology
- 3.3 Hybridoma Technology
- 3.4 Single B-Cell Technologies
- 3.5 Transgenic Animal-Based Methods
- 3.6 Other Technologies
- 4 Antibody Type
- 4.1 Antibody Type Summary
- 4.2 Monoclonal Antibodies (mAbs)
- 4.3 Polyclonal Antibodies
- 4.4 Next-Generation Antibodies
- 4.4.1 Bispecific Antibodies
- 4.4.2 Antibody-Drug Conjugates (ADCs)
- 4.4.3 Nanobodies
- 4.4.4 Other Engineered Antibodies
- 5 Nature
- 5.1 Nature Summary
- 5.2 Human Antibodies
- 5.3 Humanized Antibodies
- 5.4 Chimeric Antibodies
- 5.5 Murine Antibodies
- 6 Therapeutic Area
- 6.1 Therapeutic Area Summary
- 6.2 Oncological Disorders
- 6.3 Immunological Disorders
- 6.4 Infectious Diseases
- 6.5 Cardiovascular Disorders
- 6.6 Neurological Disorders
- 6.7 Other Therapeutic Areas
- 7 End User
- 7.1 End User Summary
- 7.2 Pharmaceutical and Biotechnology Companies
- 7.3 Contract Research Organizations (CROs)
- 7.4 Academic and Research Institutes
- 7.5 Others
- 8 Region
- 8.1 Regional Summary
- 8.2 North America
- 8.2.1 Regional Overview
- 8.2.2 Driving Factors for Market Growth
- 8.2.3 Factors Challenging the Market
- 8.2.4 By Offering
- 8.2.5 By Technology
- 8.2.6 By Country
- 8.2.6.1 U.S.
- 8.2.6.1.1 By Offering
- 8.2.6.1.2 By Technology
- 8.2.6.2 Canada
- 8.2.6.2.1 By Offering
- 8.2.6.2.2 By Technology
- 8.3 Europe
- 8.3.1 Regional Overview
- 8.3.2 Driving Factors for Market Growth
- 8.3.3 Factors Challenging the Market
- 8.3.4 By Offering
- 8.3.5 By Technology
- 8.3.6 By Country
- 8.3.6.1 U.K.
- 8.3.6.1.1 By Offering
- 8.3.6.1.2 By Technology
- 8.3.6.2 Germany
- 8.3.6.2.1 By Offering
- 8.3.6.2.2 By Technology
- 8.3.6.3 France
- 8.3.6.3.1 By Offering
- 8.3.6.3.2 By Technology
- 8.3.6.4 Italy
- 8.3.6.4.1 By Offering
- 8.3.6.4.2 By Technology
- 8.3.6.5 Spain
- 8.3.6.5.1 By Offering
- 8.3.6.5.2 By Technology
- 8.3.6.6 Sweden
- 8.3.6.6.1 By Offering
- 8.3.6.6.2 By Technology
- 8.3.6.7 Netherlands
- 8.3.6.7.1 By Offering
- 8.3.6.7.2 By Technology
- 8.3.6.8 Rest-of-Europe
- 8.3.6.8.1 By Offering
- 8.3.6.8.2 By Technology
- 8.4 Asia-Pacific
- 8.4.1 Regional Overview
- 8.4.2 Driving Factors for Market Growth
- 8.4.3 Factors Challenging the Market
- 8.4.4 By Offering
- 8.4.5 By Technology
- 8.4.6 By Country
- 8.4.6.1 Japan
- 8.4.6.1.1 By Offering
- 8.4.6.1.2 By Technology
- 8.4.6.2 China
- 8.4.6.2.1 By Offering
- 8.4.6.2.2 By Technology
- 8.4.6.3 India
- 8.4.6.3.1 By Offering
- 8.4.6.3.2 By Technology
- 8.4.6.4 Australia
- 8.4.6.4.1 By Offering
- 8.4.6.4.2 By Technology
- 8.4.6.5 South Korea
- 8.4.6.5.1 By Offering
- 8.4.6.5.2 By Technology
- 8.4.6.6 Singapore
- 8.4.6.6.1 By Offering
- 8.4.6.6.2 By Technology
- 8.4.6.7 Rest-of-Asia-Pacific
- 8.4.6.7.1 By Offering
- 8.4.6.7.2 By Technology
- 8.5 Latin America
- 8.5.1 Regional Overview
- 8.5.2 Driving Factors for Market Growth
- 8.5.3 Factors Challenging the Market
- 8.5.4 By Offering
- 8.5.5 By Technology
- 8.5.6 By Country
- 8.5.6.1 Brazil
- 8.5.6.1.1 By Offering
- 8.5.6.1.2 By Technology
- 8.5.6.2 Mexico
- 8.5.6.2.1 By Offering
- 8.5.6.2.2 By Technology
- 8.5.6.3 Argentina
- 8.5.6.3.1 By Offering
- 8.5.6.3.2 By Technology
- 8.5.6.4 Rest-of-Latin America
- 8.5.6.4.1 By Offering
- 8.5.6.4.2 By Technology
- 8.6 Middle East and Africa
- 8.6.1 Regional Overview
- 8.6.2 Driving Factors for Market Growth
- 8.6.3 Factors Challenging the Market
- 8.6.4 By Offering
- 8.6.5 By Technology
- 8.6.6 By Country
- 8.6.6.1 K.S.A.
- 8.6.6.1.1 By Offering
- 8.6.6.1.2 By Technology
- 8.6.6.2 U.A.E.
- 8.6.6.2.1 By Offering
- 8.6.6.2.2 By Technology
- 8.6.6.3 Rest of-Middle East and Africa
- 8.6.6.3.1 By Offering
- 8.6.6.3.2 By Technology
- 9 Markets - Competitive Benchmarking & Company Profiles
- 9.1 Product Mapping
- 9.1.1 By Company
- 9.1.2 By Offering
- 9.1.3 By Technology
- 9.2 Pipeline Analysis
- 9.3 Key Strategies and Developments by Company
- 9.3.1 Funding Activities
- 9.3.2 Mergers and Acquisitions
- 9.3.3 Regulatory Approvals and Product Launches
- 9.3.4 Partnerships, Collaborations, and Business Expansions
- 9.4 Company Profiles
- 9.4.1 OmniAb Inc.
- 9.4.1.1 Overview
- 9.4.1.2 Top Products/Product Portfolio
- 9.4.1.3 Top Competitors
- 9.4.1.4 Target Customers
- 9.4.1.5 Key Personal
- 9.4.1.6 Analyst View
- 9.4.2 Twist Bioscience Corporation
- 9.4.2.1 Overview
- 9.4.2.2 Top Products/Product Portfolio
- 9.4.2.3 Top Competitors
- 9.4.2.4 Target Customers
- 9.4.2.5 Key Personal
- 9.4.2.6 Analyst View
- 9.4.3 Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- 9.4.3.1 Overview
- 9.4.3.2 Top Products/Product Portfolio
- 9.4.3.3 Top Competitors
- 9.4.3.4 Target Customers
- 9.4.3.5 Key Personal
- 9.4.3.6 Analyst View
- 9.4.4 WuXi Biologics (Cayman) Inc.
- 9.4.4.1 Overview
- 9.4.4.2 Top Products/Product Portfolio
- 9.4.4.3 Top Competitors
- 9.4.4.4 Target Customers
- 9.4.4.5 Key Personal
- 9.4.4.6 Analyst View
- 9.4.5 Charles River Laboratories International, Inc.
- 9.4.5.1 Overview
- 9.4.5.2 Top Products/Product Portfolio
- 9.4.5.3 Top Competitors
- 9.4.5.4 Target Customers
- 9.4.5.5 Key Personal
- 9.4.5.6 Analyst View
- 9.4.6 Regeneron Pharmaceuticals, Inc.
- 9.4.6.1 Overview
- 9.4.6.2 Top Products/Product Portfolio
- 9.4.6.3 Top Competitors
- 9.4.6.4 Target Customers
- 9.4.6.5 Key Personal
- 9.4.6.6 Analyst View
- 9.4.7 FairJourney Biologics S.A.
- 9.4.7.1 Overview
- 9.4.7.2 Top Products/Product Portfolio
- 9.4.7.3 Top Competitors
- 9.4.7.4 Target Customers
- 9.4.7.5 Key Personal
- 9.4.7.6 Analyst View
- 9.4.8 Samsung Biologics
- 9.4.8.1 Overview
- 9.4.8.2 Top Products/Product Portfolio
- 9.4.8.3 Top Competitors
- 9.4.8.4 Target Customers
- 9.4.8.5 Key Personal
- 9.4.8.6 Analyst View
- 9.4.9 Genmab A/S
- 9.4.9.1 Overview
- 9.4.9.2 Top Products/Product Portfolio
- 9.4.9.3 Top Competitors
- 9.4.9.4 Target Customers
- 9.4.9.5 Key Personal
- 9.4.9.6 Analyst View
- 9.4.10 Alloy Therapeutics, Inc.
- 9.4.10.1 Overview
- 9.4.10.2 Top Products/Product Portfolio
- 9.4.10.3 Top Competitors
- 9.4.10.4 Target Customers
- 9.4.10.5 Key Personal
- 9.4.10.6 Analyst View
- 10 Research Methodology
- 10.1 Data Sources
- 10.1.1 Primary Data Sources
- 10.1.2 Secondary Data Sources
- 10.1.3 Data Triangulation
- 10.2 Market Estimation and Forecast
- List of Figures
- Figure 1: Global Antibody Discovery Market (by Scenario), $Billion, 2024, 2030, and 2035
- Figure 2: Global Antibody Discovery Market (by Region), $Billion, 2024 and 2035
- Figure 3: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
- Figure 4: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
- Figure 5: Global Antibody Discovery Market (by AntibodyType), $Billion, 2024, 2030, and 2035
- Figure 6: Global Antibody Discovery Market (by Nature), $Billion, 2024, 2030, and 2035
- Figure 7: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024, 2030, and 2035
- Figure 8: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
- Figure 9: Global Antibody Discovery Market, Value Chain Analysis
- Figure 10: Global Antibody Discovery Market, Patent Analysis (by Country), January 2022- August 2025
- Figure 11: Global Antibody Discovery Market, Patent Analysis (by Company), January 2022- August 2025
- Figure 12: Global Antibody Discovery Market, Patent Analysis (by Technology), January 2022- August 2025
- Figure 13: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
- Figure 14: Global Antibody Discovery Market (Antibody Discovery Platforms and Systems), $Billion, 2024-2035
- Figure 15: Global Antibody Discovery Market (Kits and Reagents), $Billion, 2024-2035
- Figure 16: Global Antibody Discovery Market (Antibody Libraries), $Billion, 2024-2035
- Figure 17: Global Antibody Discovery Market (Other Products), $Billion, 2024-2035
- Figure 18: Global Antibody Discovery Market (Antigen Designing and Preparation), $Billion, 2024-2035
- Figure 19: Global Antibody Discovery Market (Hit Generation and Screening), $Billion, 2024-2035
- Figure 20: Global Antibody Discovery Market (Lead Selection and Optimization), $Billion, 2024-2035
- Figure 21: Global Antibody Discovery Market (Antibody Engineering and Characterization), $Billion, 2024-2035
- Figure 22: Global Antibody Discovery Market (Other Services), $Billion, 2024-2035
- Figure 23: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
- Figure 24: Global Antibody Discovery Market (Phage Display Technology), $Billion, 2024-2035
- Figure 25: Global Antibody Discovery Market (Hybridoma Technology), $Billion, 2024-2035
- Figure 26: Global Antibody Discovery Market (Single B-Cell Technologies), $Billion, 2024-2035
- Figure 27: Global Antibody Discovery Market (Transgenic Animal-Based Methods), $Billion, 2024-2035
- Figure 28: Global Antibody Discovery Market (Other Technologies), $Billion, 2024-2035
- Figure 29: Global Antibody Discovery Market (by Antibody Type), $Billion, 2024, 2030, and 2035
- Figure 30: Global Antibody Discovery Market (Monoclonal Antibodies (mAbs)), $Billion, 2024-2035
- Figure 31: Global Antibody Discovery Market (Polyclonal Antibodies), $Billion, 2024-2035
- Figure 32: Global Antibody Discovery Market (Next-Generation Antibodies), $Billion, 2024-2035
- Figure 33: Global Antibody Discovery Market (Bispecific Antibodies), $Billion, 2024-2035
- Figure 34: Global Antibody Discovery Market (Antibody-Drug Conjugates(ADCs)), $Billion, 2024-2035
- Figure 35: Global Antibody Discovery Market (Nanobodies), $Billion, 2024-2035
- Figure 36: Global Antibody Discovery Market (Other Engineered Antibodies), $Billion, 2024-2035
- Figure 37: Global Antibody Discovery Market (by Nature), $Billion, 2024-2035
- Figure 38: Global Antibody Discovery Market (Human Antibodies), $Billion, 2024-2035
- Figure 39: Global Antibody Discovery Market (Humanized Antibodies), $Billion, 2024-2035
- Figure 40: Global Antibody Discovery Market (Chimeric Antibodies), $Billion, 2024-2035
- Figure 41: Global Antibody Discovery Market (Murine Antibodies), $Billion, 2024-2035
- Figure 42: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024-2035
- Figure 43: Global Antibody Discovery Market (Oncological Disorders), $Billion, 2024-2035
- Figure 44: Global Antibody Discovery Market (Immunological Disorders), $Billion, 2024-2035
- Figure 45: Global Antibody Discovery Market (Infectious Diseases), $Billion, 2024-2035
- Figure 46: Global Antibody Discovery Market (Cardiovascular Disorders), $Billion, 2024-2035
- Figure 47: Global Antibody Discovery Market (Neurological Disorders), $Billion, 2024-2035
- Figure 48: Global Antibody Discovery Market (Other Therapeutic Areas), $Billion, 2024-2035
- Figure 49: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
- Figure 50: Global Antibody Discovery Market (Pharmaceutical and Biotechnology Companies), $Billion, 2024-2035
- Figure 51: Global Antibody Discovery Market (Contract Research Organizations(CROs)), $Billion, 2024-2035
- Figure 52: Global Antibody Discovery Market (Academic and Research Institutes), $Billion, 2024-2035
- Figure 53: Global Antibody Discovery Market (Others), $Billion, 2024-2035
- Figure 54: U.S. Antibody Discovery Market, $Billion, 2024-2035
- Figure 55: Canada Antibody Discovery Market, $Billion, 2024-2035
- Figure 56: Europe Antibody Discovery Market, $Billion, 2024-2035
- Figure 57: U.K. Antibody Discovery Market, $Billion, 2024-2035
- Figure 58: Germany Antibody Discovery Market, $Billion, 2024-2035
- Figure 59: France Antibody Discovery Market, $Billion, 2024-2035
- Figure 60: Italy Antibody Discovery Market, $Billion, 2024-2035
- Figure 61: Spain Antibody Discovery Market, $Billion, 2024-2035
- Figure 62: Sweden Antibody Discovery Market, $Billion, 2024-2035
- Figure 63: nds Antibody Discovery Market, $Billion, 2024-2035
- Figure 64: Rest-of-Europe Antibody Discovery Market, $Billion, 2024-2035
- Figure 65: Japan Antibody Discovery Market, $Billion, 2024-2035
- Figure 66: China Antibody Discovery Market, $Billion, 2024-2035
- Figure 67: India Antibody Discovery Market, $Billion, 2024-2035
- Figure 68: Australia Antibody Discovery Market, $Billion, 2024-2035
- Figure 69: South Korea Antibody Discovery Market, $Billion, 2024-2035
- Figure 70: Singapore Antibody Discovery Market, $Billion, 2024-2035
- Figure 71: Rest-of-Asia-Pacific Antibody Discovery Market, $Billion, 2024-2035
- Figure 72: Brazil Antibody Discovery Market, $Billion, 2024-2035
- Figure 73: Mexico Antibody Discovery Market, $Billion, 2024-2035
- Figure 74: Mexico Antibody Discovery Market, $Billion, 2024-2035
- Figure 75: Rest-of-Latin America Antibody Discovery Market, $Billion, 2024-2035
- Figure 76: K.S.A. Antibody Discovery Market, $Billion, 2024-2035
- Figure 77: U.A.E. Antibody Discovery Market, $Billion, 2024-2035
- Figure 78: Rest-of-Middle East and Africa Antibody Discovery Market, $Billion, 2024-2035
- Figure 79: Global Antibody Discovery Market, Product Mapping (by Company)
- Figure 80: Data Triangulation
- Figure 81: Top-Down and Bottom-Up Approach
- Figure 82: Assumptions and Limitations
- List of Tables
- Table 1: Market Snapshot
- Table 2: Pricing Analysis (by Region)
- Table 3: Antibody Discovery Market (by Region), $Billion, 2024-2035
- Table 4: North America Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 5: North America Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 6: U.S. Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 7: U.S. Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 8: Canada Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 9: Canada Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 10: Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 11: Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 12: U.K. Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 13: U.K. Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 14: Germany Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 15: Germany Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 16: France Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 17: France Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 18: Italy Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 19: Italy Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 20: Spain Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 21: Spain Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 22: Sweden Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 23: Sweden Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 24: Netherlands Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 25: Netherlands Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 26: Rest-of-Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 27: Rest-of-Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 28: Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 29: Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 30: Japan Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 31: Japan Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 32: China Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 33: China Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 34: India Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 35: India Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 36: Australia Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 37: Australia Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 38: South Korea Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 39: South Korea Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 40: Singapore Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 41: Singapore Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 42: Rest-of-Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 43: Rest-of-Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 44: Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 45: Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 46: Brazil Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 47: Brazil Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 48: Mexico Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 49: Mexico Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 50: Argentina Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 51: Argentina Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 52: Rest-of-Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 53: Rest-of-Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 54: Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 55: Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 56: K.S.A. Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 57: K.S.A. Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 58: U.A.E. Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 59: U.A.E. Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 60: Rest-of-Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
- Table 61: Rest-of-Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
- Table 62: Global Antibody Discovery Market, Product Mapping (by Offering)
- Table 63: Global Antibody Discovery Market
- Table 64: Pipeline Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.